Monopar Therapeutics MNPR 深 滬
已收盤 09-12 16:00:00 美东时间
49.22
+1.555
+3.26%
華盛通- 最 高49.81
- 今 開47.89
- 成交量 2.24万股
- 最 低 45.52
- 昨 收 47.665
- 總市值 3.04亿
- 52周最高 54.30
- 市盈率 靜 --
- 換手率 0.36%
- 52周最低 4.12
- 委 比 -74.67%
- 總股本 617.00万
- 歷史最高 240.00
- 量 比 0.68
- 振 幅 9.00%
- 歷史最低 1.3695
- 每 手 1
- 風險率 12.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅577.08%！Veritone获D. Boral Capital升目标价至26美元，维持"买入"评级
今日重点评级关注：D. Boral Capital：维持Veritone"买入"评级，目标价从6美元升至26美元；Guggenheim：维持Dianthus Therapeutics"买入"评级，目标价从92美元升至100美元
09-10 18:01
美股大行评级 | 潜在涨幅403.28%！瑞杰金融首予Kalaris Therapeutics"强烈买入"评级，目标价23美元
今日重点评级关注：花旗：维持Ionis Pharmaceuticals"买入"评级，目标价从69美元升至84美元；Melius Research：上调康明斯评级至"买入"，目标价500美元
09-04 09:49
Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting
Monopar Therapeutics Inc. announced that its research on ALXN1840 for Wilson disease has been selected as a distinguished abstract for both oral and poster presentations at the 150th ANA Annual Meeting. The study highlights long-term neurological benefits in patients and will be presented by Matthew Lorincz, M.D., Ph.D. from the University of Michigan. Additionally, Monopar is developing radiopharmaceutical programs for advanced cancer treatment ...
09-03 12:00
Monopar Therapeutics files $300M mixed securities shelf
Monopar Therapeutics (NASDAQ:MNPR) filed $300 million mixed securities shelf. Filing More on Monopar Therapeutics Seeking Alpha’s Quant Rating on Monopar Therapeutics Historical earnings data for Mono...
08-30 04:52
HC Wainwright & Co. Assumes Monopar Therapeutics at Buy, Announces Price Target of $70
HC Wainwright & Co. analyst Andres Y. Maldonado assumes Monopar Therapeutics (NASDAQ:MNPR) with a Buy rating and announces Price Target of $70.
08-26 19:08
Monopar Therapeutics shares are trading higher after the company reported a Q2 EPS beat.
Monopar Therapeutics shares are trading higher after the company reported a Q2 ...
08-13 03:25
Monopar Therapeutics Q2 EPS $(0.35) Beats $(0.49) Estimate
Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.49) by 28.57 percent. This is a 28.57 percent increase over losses of $(0.49) per share
08-12 20:08
Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments
Monopar Therapeutics announced second quarter 2025 financial results and recent developments. Alexion transferred the IND for ALXN1840 to Monopar, with FDA confirmation. Monopar plans to submit an NDA for ALXN1840 in early 2026. MNPR-101 trials are ongoing in Australia, with an Expanded Access Program in the U.S. Cash as of June 30, 2025, was $53.3 million, expected to support operations through 2026. Net loss for the quarter was $2.5 million, up...
08-12 12:00
美股大行评级 | 潜在涨幅199.47%！杰富瑞上调Cogent Biosciences目标价至28美元，维持"买入"评级
今日重点评级关注：杰富瑞：维持Cogent Biosciences"买入"评级，目标价从23美元升至28美元；Leerink Partners：维持Cogent Biosciences"跑赢大市"评级，目标价从16美元升至18美元
07-08 09:34
